目的:比较多西他塞(TXT)与奥沙利铂(L-OHP)分别联合替吉奥(S-1)治疗晚期胃癌的有效性和安全性.方法:54例晚期胃癌患者分为两组,A组(TXT+S-1)30例,TXT 75 mg/m2静滴2h,d1；S-1 80mg 分早晚2次餐后服用,d1-d14；B组(L-OHP+S-1)24例,L-OHP 130mg/m2静滴2h,d1；S-1 80mg分早晚2次餐后服用,d1-d14.两组均3周为1周期,2个周期评价疗效及毒性,随访疾病进展时间和生存期.结果:A、B两组的有效率分别为46.6％和54.2％,疾病控制率为70％和75％,中位疾病进展时间为6.6个月和6.8个月,中位生存时间为13.5个月和14.0个月,差异均无统计学意义(P＞0.05).两组毒副反应主要包括血液学毒性、肝肾功能异常、恶心呕吐、腹泻、末梢神经毒性和过敏反应等,以1-2级为主,均可耐受.结论:TXT联合S-1与L-OHP联合S-1治疗晚期胃癌的疗效相当,不良反应均可耐受.%Objective:To evaluate the efficacy and toxicity of oxaliplatin (L-OHP) or docetaxel (TXT) combined with S-1 in patients with advanced gastric cancer.Methods:All 54 patients with advanced gastric cancer were enrolled and divided into two groups.Group A (TXT + S-1):30 patients received TXT of 75mg/m2 on day 1 and S -1 of 80mg orally twice daily after meal on day 1 to 14,every 3 weeks.Group B (L-OHP + S-1):24 patients received L-OHP 130 mg/m2 on day 1 and S-1 80mg orally twice daily after meal on day 1 to 14,every 3 weeks.Assessment of response was performed every two cycles according to RECIST criteria.The time to progress and overall survival were observed.Results:In group A and group B,the response rates (RR) were 46.6 ％ and 54.2％ respectively,the disease control rates(DCR) were 70％ and 75％,the median time to progress were 6.6 and 6.8 months,and the median overall survival(OS) were 13.5 and 14.0 months.There was no significant difference between group A and group B (P ＞ 0.05).Side effects in the two groups were similar and well tolerated.Conclusion:TXT plus S-1 and L-OHP plus S-1 are active therapeutic equivalence and well tolerated in patients with advanced gastric cancer.
展开▼
